In Reply Our randomized trial demonstrated a consistent improvement in both progression-free and overall survival when TTFields was included in first-line therapy for glioblastoma. The hazard ratio for death was 0.63, translating into an improvement in the 2-year survival rate from 31% to 43%. For comparison, the addition of temozolomide to radiotherapy compared with radiotherapy alone also resulted in a hazard ratio of 0.63, with a 2-year survival rate increasing from 10% to 27%.1 One may consider the improvements modest, yet these are the most effective proven treatments available.
Stupp R, Ram Z. Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields—Reply. JAMA. 2018;319(17):1823. doi:10.1001/jama.2018.1862
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: